Related Experiment Video
Updated: Jul 1, 2026

Establishment of an Experimental Mouse Model of Endometrioma to Study its Related Infertility
Published on: April 5, 2024
Endometriosis management: workflow on genomics and proteomics and future biomolecular pharmacotherapy
Andrea Tinelli1, Roberta Martignago, Daniele Vergara
1Department of Obstetrics and Gynecology, Vito Fazzi Hospital, Lecce, Italy. andreatinelli@gmail.com
Background:
Endometriosis is an estrogen-dependent disease, associated with pelvic pain and infertility, with still limited knowledge of the pathogenesis, pathophysiology of related infertility and evolution.
Objective:
To investigate proteogenomic approaches and new trends of endometriosis treatment.
Methods:
A literature search was carried out for all articles on endometriosis related to immune system, and to non-hormonal, antiangiogenic and experimental therapies.
Results/Conclusions:
Classic endometriosis pharmacotherapy is represented by GnRH agonists, oral contraceptives and Type II progesterone receptor ligands. New proteomic and genomic technologies could help to clarify the aetiology of endometriosis and promise the rapid identification of a new generation of drugs with a specific molecular target, with the aim to ameliorate the patients' quality of life.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Genomics
Pharmacogenetics and Pharmacogenomics: Overview
Proteomics
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
